EUVIMEDEUVIMED entdecken
Crossref

Development of a 18 F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer

Qianqian Gan, Kai Cui, Qi Cao, Ning Zhang, Min-Fu Yang, Xing Yang iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Qianqian Gan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020,…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Erythropoietin. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Institute of Respiratory Medicine, Capital Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although PSMA PET/CT imaging has great potential for noninvasively detecting prostate cancer (PCa), limitations exist for patients with low PSMA expression, caused by androgen deprivation treatment or neuroendocrine differentiation. Analysis of The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) data found that erythropoietin-producing hepatocellular receptor A2 (EphA2), a receptor overexpressed in most PCa could be a potential target for PSMA-negative PCa. A fluorescent ligand ETF and a radiolabeled ligand [18F]AlF-ETN derived from a EphA2-targeting bicyclic peptide were synthesized and investigated. ETF could selectively stain and visualize the EphA2-positive but PSMA-negative PC3 cells, in complementary to the PSMA-targeting probe. PET/CT imaging and biodistribution experiments demonstrated that [18F]AlF-ETN specifically accumulated in PC3 tumors with a high contrast (tumor-to-muscle ratio: 21.29 ± 6.55). In conclusion, we have demonstrated the potential for using EphA2 to detect PSMA-negative PCa and developed a radiolabeled ligand [18F]AlF-ETN to specifically image EphA2 expressing PCa with high contrast.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsErythropoietinMaleHumansPositron Emission Tomography Computed TomographyReceptors, ErythropoietinLigandsTissue DistributionAndrogen AntagonistsPeptidesMolecular Imaging

Substanzen

Receptors, ErythropoietinLigandsAndrogen AntagonistsPeptidesErythropoietin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
  • Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
  • Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China.
  • Yunnan Baiyao Group, Kunming 650000, China.
  • Laboratorial Center, Peking University First Hospital, Beijing 100034, China.

ORCID-Profile: Xing Yang

Förderung

  • National Natural Science Foundation of China
  • Beijing Institute of Respiratory Medicine, Capital Medical University

Zitieren

APA

Gan, Q., Cui, K., Cao, Q., Zhang, N., Yang, M. F., & Yang, X. (2023). Development of a 18 F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01135

Vancouver

Gan Q, Cui K, Cao Q, Zhang N, Yang MF, Yang X. Development of a 18 F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01135

BibTeX
@article{Gan2023,
  author = {Gan, Qianqian and Cui, Kai and Cao, Qi and Zhang, Ning and Yang, Min-Fu and Yang, Xing},
  title = {Development of a 18 F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01135}
}
Kostenlos starten →